65,437 trials
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Peak Forced Expiratory Volume in One Second (FEV1) at Week 24 — 1.655; 1.562 Liters — p=<0.001
Traumatic Brain Injury
Primary: Safety and Tolerability of VAS203 in Patients With Moderate and Severe TBI — 8; 8; 6; 8 participants
Arterial Thromboembolic Events · Atrial Fibrillation
Primary: Number of Arterial Thromboembolic Events — 2; 3; 2; 0 Arterial thromboembolic events
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Epidural Analgesia, Obstetric
Primary: Maximum Plasma Concentration (Cmax) of Extended Release Epidural Morphine (EREM) — 11.1; 8.3 ng/mL
Vitamin D Deficiency
Primary: Number of Participants Who Develop Hypercalcemia — 0; 2 participants
Colorectal Cancer (CRC) Screening
Primary: Percentage Subjects With Post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS) Adequate Cleansing-(BBPS>1 ) — 88.9 percentage of…
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study — -7.63; -7.94 millimeter(s) of mercury (mmHg) — p=0.0040
Operation Site Bleed
Primary: The Primary Objective of This Investigation is to Gather Information to Support the Effectiveness of Thrombi-Gel as Compared to a Gelatin Sponge (Gelfoam) Plus Thrombin…
Left Ventricular Dysfunction · Right Ventricular Dysfunction · Pulmonary Hypertension
Primary: Percentage of Correct Diagnosis — 61; 31; 47; 6 percentage of correct diagnosis
Conjunctivitis, Allergic
Primary: Ocular Itching Score — 0.33; 1.48; 0.29 score on a scale
Sickle Cell Disease
Primary: Number of Participants With Grade 2 or Higher Adverse Event According to NCI Criteria — 0 participants
Arrhythmias, Cardiac
Primary: Percentage of Participants in Whom Pericardial Access Was Achieved With the EpiAccess System — 100 percentage of patients
Leukemia, Myelocytic, Acute · Leukemia, Lymphocytic, Acute · Leukemia, Myeloid, Chronic
Primary: Rate of Grades II-IV Acute GVHD-free Survival — 67; 62 percentage of participants